Abstract
About this talk
Since 2013, the Russian Federation has been using the new anti-TB drug Bedaquiline (Sirturo), whose mechanism of action is radically different from the existing anti-TB drugs. The drug has shown its high effectiveness in the treatment of drug resistant tuberculosis. In phase III clinical trials, the bedaquiline group showed a significant increase in the number of deaths without an obvious causal factor, compared with the placebo group (12.7 vs. 2.5%). Despite the high efficacy of bedaquiline, community CRAG experts expressed concerns about the safety of the drug and said that more information on the safety of Bedaquiline was urgently needed.
Speaker
About the speaker
